Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
2017 · New England Journal of Medicine · 995 citations
https://doi.org/10.1056/nejmoa1702079
F
Frank Moosig
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
193
Papers
7.2K
Citations
42
h-index
79
i10-index
Frank Moosig is an academic researcher from Independent Centre for Privacy Protection. The author has contributed to research in topics: Vasculitis and related conditions & Eosinophilic Disorders and Syndromes & Urticaria and Related Conditions. The author has an h-index of 42, co-authored 165 publications.
ORCID: 0000-0002-7341-9844Papers by this author
worksGenome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
2019 · Nature Communications · 264 citations
https://doi.org/10.1038/s41467-019-12515-9
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
2023 · Nature Reviews Rheumatology · 264 citations
https://doi.org/10.1038/s41584-023-00958-w
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
2021 · Arthritis & Rheumatology · 153 citations
https://doi.org/10.1002/art.41943
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
2013 · Current Opinion in Rheumatology · 144 citations
https://doi.org/10.1097/bor.0000000000000015
Influence of the IL17A locus in giant cell arteritis susceptibility
2014 · Annals of the Rheumatic Diseases · 43 citations
https://doi.org/10.1136/annrheumdis-2014-205261
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat